Last updated: 11/07/2018 07:08:29

Meta-analysis - eltrombopag

GSK study ID
114013
See study documents
Clinicaltrials.gov ID
NCT01235988
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Systematic review of the clinical and cost effectiveness of treatments for idiopathic (immune) thrombocytopenic purpura (ITP): direct meta analysis
Trial description: The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

>=50 Gi/L platelet count to <400 Gi/L

Timeframe: 43 days

Secondary outcomes:
Not applicable
Interventions:
  • Drug: Eltrombopag
  • Drug: Placebo
    • Enrollment:
    1
    Primary completion date:
    Not applicable
    Observational study model:
    Other
    Time perspective:
    Retrospective
    Clinical publications:
    Boyers D, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura - A NICE Single Technology Appraisal. [Pharmacoeconomics]. 2012;30(6):483-495.
    Medical condition
    Thrombocytopaenia
    Product
    eltrombopag
    Collaborators
    Not applicable
    Study date(s)
    August 2009 to November 2009
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    No
    • Adults with ITP
    • Received a pre-specified treatment
    • Subjects with ITP due to other causes
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Adults with ITP
    • Received a pre-specified treatment
    • Prospective clinical studies with at least 10 patients
    Exclusion criteria:
    • Subjects with ITP due to other causes

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2009-30-11

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website